infohep news

• New Prognosis and disease progression

  Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US

  Keith Alcorn / 5 hours ago

  The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced fibrosis or cirrhosis and therefore being at ...

• New Deciding when and how to treat HCV

  Deferring hepatitis C treatment can lead to liver cancer and death, despite cure

  Keith Alcorn / 5 hours ago

  People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ...

• Treatment for people living with HIV and HCV

  Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

  Liz Highleyman / 04 March 2015

  A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis C for more than 95% of ...

• Protease inhibitors

  AbbVie next-generation hepatitis C drugs look promising in early studies

  Liz Highleyman / 03 March 2015

  AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a three-day monotherapy study, as well as potent and synergistic ...

• Interferon treatment for HBV

  Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients

  Liz Highleyman / 05 February 2015

  People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir -- ...